These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29224996)

  • 1. Cost-effectiveness of the non-laboratory based Framingham algorithm in primary prevention of cardiovascular disease: A simulated analysis of a cohort of African American adults.
    Kariuki JK; Gona P; Leveille SG; Stuart-Shor EM; Hayman LL; Cromwell J
    Prev Med; 2018 Jun; 111():415-422. PubMed ID: 29224996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines.
    Pandya A; Weinstein MC; Salomon JA; Cutler D; Gaziano TA
    Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):25-32. PubMed ID: 24425701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease risk prediction in sub-Saharan African populations - Comparative analysis of risk algorithms in the RODAM study.
    Boateng D; Agyemang C; Beune E; Meeks K; Smeeth L; Schulze MB; Addo J; de-Graft Aikins A; Galbete C; Bahendeka S; Danquah I; Agyei-Baffour P; Owusu-Dabo E; Mockenhaupt FP; Spranger J; Kengne AP; Grobbee DE; Klipstein-Grobusch K
    Int J Cardiol; 2018 Mar; 254():310-315. PubMed ID: 29407113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the nonlaboratory-based Framingham cardiovascular disease risk assessment algorithm in the Atherosclerosis Risk in Communities dataset.
    Kariuki JK; Stuart-Shor EM; Leveille SG; Gona P; Cromwell J; Hayman LL
    J Cardiovasc Med (Hagerstown); 2017 Dec; 18(12):936-945. PubMed ID: 29045312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
    Shiffman D; Slawsky K; Fusfeld L; Devlin JJ; Goss TF
    Clin Ther; 2012 Jun; 34(6):1387-94. PubMed ID: 22560621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study.
    Hippisley-Cox J; Coupland C; Vinogradova Y; Robson J; May M; Brindle P
    BMJ; 2007 Jul; 335(7611):136. PubMed ID: 17615182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of implementing risk-based cardiovascular disease (CVD) management using updated WHO CVD risk prediction charts in India.
    Sivanantham P; S MK; Essakky S; Singh M; Ghosh S; Mehndiratta A; Kar SS
    PLoS One; 2023; 18(8):e0285542. PubMed ID: 37624838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A computer-guided quality improvement tool for primary health care: cost-effectiveness analysis based on TORPEDO trial data.
    Patel B; Peiris DP; Patel A; Jan S; Harris MF; Usherwood T; Panaretto K; Lung T
    Med J Aust; 2020 Jul; 213(2):73-78. PubMed ID: 32594567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study.
    De Socio GV; Pucci G; Baldelli F; Schillaci G
    BMC Infect Dis; 2017 Jun; 17(1):414. PubMed ID: 28606059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative assessment of absolute cardiovascular disease risk characterization from non-laboratory-based risk assessment in South African populations.
    Gaziano TA; Pandya A; Steyn K; Levitt N; Mollentze W; Joubert G; Walsh CM; Motala AA; Kruger A; Schutte AE; Naidoo DP; Prakaschandra DR; Laubscher R
    BMC Med; 2013 Jul; 11():170. PubMed ID: 23880010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
    Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
    BMC Health Serv Res; 2016 May; 16():185. PubMed ID: 27184802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for future cardiovascular disease using age alone compared with multiple risk factors and age.
    Wald NJ; Simmonds M; Morris JK
    PLoS One; 2011 May; 6(5):e18742. PubMed ID: 21573224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and cost-effectiveness of a cardiovascular risk prediction algorithm for people with severe mental illness (PRIMROSE).
    Zomer E; Osborn D; Nazareth I; Blackburn R; Burton A; Hardoon S; Holt RIG; King M; Marston L; Morris S; Omar R; Petersen I; Walters K; Hunter RM
    BMJ Open; 2017 Sep; 7(9):e018181. PubMed ID: 28877952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease.
    Špacírová Z; Kaptoge S; García-Mochón L; Rodríguez Barranco M; Sánchez Pérez MJ; Bondonno NP; Tjønneland A; Weiderpass E; Grioni S; Espín J; Sacerdote C; Schiborn C; Masala G; Colorado-Yohar SM; Kim L; Moons KGM; Engström G; Schulze MB; Bresson L; Moreno-Iribas C; Epstein D
    Eur J Health Econ; 2023 Sep; 24(7):1033-1045. PubMed ID: 36239877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population].
    Si YQ; Tang X; Zhang DD; He L; Cao Y; Wang JW; Li N; Liu JJ; Gao P; Hu YH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 50(3):443-449. PubMed ID: 29930411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms.
    Zomer E; Liew D; Owen A; Magliano DJ; Ademi Z; Reid CM
    Eur J Prev Cardiol; 2014 Mar; 21(3):384-90. PubMed ID: 22588087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling.
    Perera R; McFadden E; McLellan J; Lung T; Clarke P; Pérez T; Fanshawe T; Dalton A; Farmer A; Glasziou P; Takahashi O; Stevens J; Irwig L; Hirst J; Stevens S; Leslie A; Ohde S; Deshpande G; Urayama K; Shine B; Stevens R
    Health Technol Assess; 2015 Dec; 19(100):1-401, vii-viii. PubMed ID: 26680162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk estimation versus screening performance: a comparison of six risk algorithms for cardiovascular disease.
    Simmonds MC; Wald NJ
    J Med Screen; 2012 Dec; 19(4):201-5. PubMed ID: 23293165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in Cardiovascular Mortality Risk among African Americans in the Minnesota Heart Survey: 1985-2015 vs The Atherosclerosis Risk in Communities Study Cohort: 1987-2015.
    George KM; Folsom AR; Steffen LM; Wagenknecht LE; Mosley TH
    Ethn Dis; 2019; 29(1):47-52. PubMed ID: 30713416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.